Zura Bio (NASDAQ:ZURA) Stock Price Down 7.2% – Here’s Why

Zura Bio Limited (NASDAQ:ZURA) traded down 7.2% during mid-day trading on Wednesday . The company traded as low as $5.71 and last traded at $5.6860. 516,569 shares changed hands during mid-day trading, a decline of 44% from the average daily volume of 920,024 shares. The stock had previously closed at $6.13.

Analysts Set New Price Targets

ZURA has been the topic of several analyst reports. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Guggenheim increased their price objective on shares of Zura Bio from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. William Blair initiated coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Finally, Wedbush boosted their price target on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Zura Bio Stock Down 6.9%

The company has a market capitalization of $546.71 million, a P/E ratio of -5.05 and a beta of -0.02. The firm has a 50-day moving average price of $5.59 and a two-hundred day moving average price of $5.37.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, analysts predict that Zura Bio Limited will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Several institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in Zura Bio during the 2nd quarter worth about $28,000. Allworth Financial LP acquired a new position in Zura Bio in the 4th quarter valued at about $30,000. Squarepoint Ops LLC raised its holdings in Zura Bio by 34.6% in the 4th quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock valued at $177,000 after acquiring an additional 8,680 shares during the period. Bank of America Corp DE boosted its holdings in shares of Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Zura Bio by 3.4% in the first quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock valued at $1,864,000 after purchasing an additional 10,200 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.